Low dose rate brachytherapy monotherapy across risk groups

New registry data from the Cleveland Clinic shows good oncological control with low dose rate brachytherapy (LDRBT) monotherapy, at least for low-risk and low  intermediate-risk groups. This is the first time I’ve seen LDRBT monotherapy data for higher-risk groups. … READ MORE …

International group creates better gene map for men with mCRPC

A new article in the journal Cell is being said to “clarify the genetic backgrounds of men with metastatic, castration-resistant prostate cancer” (mCRPC). It also suggests that most cases of prostate cancer are “sensitive to drugs already available or under development.” … READ MORE …

Other items from the annual meeting of the AUA

A combination of travel and other commitments made it difficult for your sitemaster to complete his summaries of significant information presented at this year’s annual meeting of the American Urological Association (AUA), so here’s the final wrap-up. … READ MORE …

US national prostate cancer registry coming to life soon

At the annual meeting of the American Urological Association (AUA) this morning, Dr. Matt Cooperberg reported that a total of 450 US-based urologists had now signed up to contribute data on their prostate cancer patients to the AQUA Registry. … READ MORE …

Intense discussion of the future of focal therapy in prostate cancer

At a 4-hour meeting yesterday afternoon here in New Orleans there was intense discussion of issues related to the future of focal therapy and (potentially) to the approval of new types of device and technologies that might be able to deliver focal therapy. … READ MORE …

STRIVE trial again shows benefits to enzalutamide vs. bicalutamide

Earlier this year results from the TERRAIN trial reported that adding enzalutamide (Xtandi) to LHRH agonist therapy was more effective than adding the antiandrogen bicalutamide in men with metastatic, castration-resistant prostate cancer ( M1 CRPC). … READ MORE …

ADT and radiation for first-line treatment of node-positive (N1) prostate cancer

It’s now a relatively rare occurrence (about 12 percent of new patients) to be newly diagnosed with pelvic lymph node positive (N1) prostate cancer. Traditionally, this had been treated with ADT only because radiation therapy (RT) was thought to be of no benefit in extending survival. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,294 other followers